76 related articles for article (PubMed ID: 26616436)
41. Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients.
Ibayashi Y; Yamaki T; Kawahara T; Daibo M; Kubota T; Uede T; Tanabe S; Hashi K
Neurol Med Chir (Tokyo); 1993 Jul; 33(7):448-57. PubMed ID: 7692323
[TBL] [Abstract][Full Text] [Related]
42. Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor.
Burdach S; Zessack N; Dilloo D; Shatsky M; Thompson D; Levitt L
J Clin Invest; 1991 Jun; 87(6):2114-21. PubMed ID: 1828253
[TBL] [Abstract][Full Text] [Related]
43. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.
Yoshida H; Katayose Y; Unno M; Suzuki M; Kodama H; Takemura S; Asano R; Hayashi H; Yamamoto K; Matsuno S; Kudo T
Cancer Immunol Immunother; 2003 Feb; 52(2):97-106. PubMed ID: 12594573
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
45. Acidic polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2.
Kim KH; Lee YS; Jung IS; Park SY; Chung HY; Lee IR; Yun YS
Planta Med; 1998 Mar; 64(2):110-5. PubMed ID: 9525101
[TBL] [Abstract][Full Text] [Related]
46. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
47. Reduced cytokine secretions by LAK cells of pulmonary tuberculosis patients in response to tumor targets in vitro.
Nirmala R; Mathew R; Narayanan PR
J Interferon Cytokine Res; 2002 Jun; 22(6):617-20. PubMed ID: 12162871
[TBL] [Abstract][Full Text] [Related]
48. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
Yamaguchi Y; Hironaka K; Okawaki M; Okita R; Matsuura K; Ohshita A; Toge T
Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
[TBL] [Abstract][Full Text] [Related]
49. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
Hayakawa M
Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
[TBL] [Abstract][Full Text] [Related]
50. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.
Schrezenmeier H; Thomé SD; Tewald F; Fleischer B; Raghavachar A
Exp Hematol; 1993 Feb; 21(2):358-65. PubMed ID: 8425573
[TBL] [Abstract][Full Text] [Related]
52. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
[TBL] [Abstract][Full Text] [Related]
53. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
54. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
55. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis.
Savary CA; Lotzová E
Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234
[TBL] [Abstract][Full Text] [Related]
56. Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion.
Kuppen PJ; Marinelli A; Camps JA; Pauwels EK; van de Velde CJ; Fleuren GJ; Eggermont AM
Int J Cancer; 1992 Sep; 52(2):266-70. PubMed ID: 1521913
[TBL] [Abstract][Full Text] [Related]
57. Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats.
Maeta N; Tamura K; Takemitsu H; Miyabe M
Open Vet J; 2019 Jul; 9(2):147-150. PubMed ID: 31360654
[TBL] [Abstract][Full Text] [Related]
58. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy.
Haruta I; Yamauchi K; Aruga A; Komatsu T; Takasaki K; Hayashi N; Hanyu F
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):218-23. PubMed ID: 8811496
[TBL] [Abstract][Full Text] [Related]
59. Prevention of in vivo alloreactions by adoptive immunotherapy with lymphokine-activated killer cells.
Kaplan J; Uberti J
Ann N Y Acad Sci; 1991 Dec; 636():380-2. PubMed ID: 1793223
[No Abstract] [Full Text] [Related]
60. Characterization of the pulmonary lesions induced in rats by human recombinant interleukin-2.
Zhang J; Wenthold RJ; Yu ZX; Herman EH; Ferrans VJ
Toxicol Pathol; 1995; 23(6):653-66. PubMed ID: 8772251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
